Related Experiment Video
Updated: Aug 5, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Explaining reduced cancer survival among the disadvantaged
H P Greenwald1, E F Borgatta, R McCorkle
1Sacramento Center, University of Southern California 95814-2919, USA. Greenwa@mizar.usc.edu
The Milbank Quarterly
|January 1, 1996
Summary
Socially disadvantaged cancer patients have higher mortality risks. While improved healthcare access can help, it won't fully equalize survival chances compared to advantaged patients.
Area of Science:
- Oncology
- Health Disparities
- Social Determinants of Health
Background:
- Socially disadvantaged cancer patients exhibit higher mortality rates than their advantaged counterparts.
- The underlying reasons for these survival disparities remain incompletely understood.
- Existing research points to intricate links between biological, medical, and social factors.
Purpose of the Study:
- To investigate the complex interrelations determining survival differences in cancer patients.
- To explore the impact of social differentiation on cancer patient outcomes.
- To evaluate the potential of improved healthcare access in mitigating survival disparities.
Main Methods:
- Analysis of a newly completed 10-year cancer survival study.
- Examination of biological factors, medical interventions, and social dimensions.
- Application of economic and cognitive-behavioral models to survival determinants.
Main Results:
- Survival differences are shaped by complex interactions of biological, medical, and social factors.
- Cancer survival patterns align with an "economic" model for some cancers and a "cognitive-behavioral" model for others.
- Improved healthcare access demonstrated a reduction in mortality risk for disadvantaged patients in certain malignancies.
Conclusions:
- While improved healthcare access is beneficial, it is insufficient to achieve equal survival outcomes for disadvantaged cancer patients.
- Addressing social determinants of health is crucial for reducing cancer mortality disparities.
- Further research is needed to fully understand and address the multifaceted nature of cancer survival inequalities.
Related Concept Videos
02:53Adaptive Mechanisms in Cancer Cells
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:59Cancer Prevention
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:24Kaplan-Meier Approach
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
01:20Comparing the Survival Analysis of Two or More Groups
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...